- Previous Close
9.12 - Open
9.14 - Bid 8.78 x 100
- Ask 9.01 x 100
- Day's Range
8.76 - 9.14 - 52 Week Range
8.75 - 17.02 - Volume
194,209 - Avg. Volume
114,260 - Market Cap (intraday)
579.22M - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-3.63 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
36.43
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
www.abivax.comRecent News: ABVX
View More
Performance Overview: ABVX
Trailing total returns as of 11/19/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABVX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABVX
View MoreValuation Measures
Market Cap
566.59M
Enterprise Value
348.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.70
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.69%
Return on Equity (ttm)
-171.46%
Revenue (ttm)
9.03M
Net Income Avi to Common (ttm)
-177.42M
Diluted EPS (ttm)
-3.63
Balance Sheet and Cash Flow
Total Cash (mrq)
222.32M
Total Debt/Equity (mrq)
89.64%
Levered Free Cash Flow (ttm)
-89.3M
Research Analysis: ABVX
View MoreCompany Insights: ABVX
ABVX does not have Company Insights